Cediranib
Secondary Amyloidosis
City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Secondary Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II City of Hope Medical Center | Phase 2 | B |
DARATUMUMAB City of Hope Medical Center | Phase 2 | B |
DEXAMETHASONE City of Hope Medical Center | Phase 2 | B |
FILGRASTIM City of Hope Medical Center | Phase 2 | B |
Evomela City of Hope Medical Center | Phase 2 | CCC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →